Chamber and committees

I refer the member to the answer to question S6W-10433 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

As part of the Scottish Medicines Consortium’s (SMC) continuing role in the UK-wide multi-agency RAPID C-19 initiative, the collaborative partnership between the SMC and the National Institute for Health and Care Excellence (NICE) will extend to the multiple technology assessment (MTA) of the range of therapeutics for the treatment of COVID-19; therefore, a separate assessment of these medicines by the SMC will not be required.

My intention is to update Parliament with our Winter Resilience plans and publish our Winter Resilience Overview, covering both the NHS and Social Care, early next month, subject to discussions at Parliamentary Bureau. Caroline Lamb, CEO of NHS Scotland has also already written to NHS Boards and Integration Authorities regarding winter resilience plans at a national level and setting out clear expectations for local resilience and response.

The Scottish Medicines Consortium (SMC) is a partner in a UK-wide multi-agency RAPID C-19 initiative, which is a collaborative partnership between the SMC and the National Institute for Health and Care Excellence (NICE). Building on this work, the SMC is exploring the potential for collaboration with NICE on a single technology assessment (STA) of tixagevimab–cilgavimab (Evusheld ® ) for the prevention of COVID-19.

The Scottish Government has had very constructive discussions with AstraZeneca on Evusheld ® for the preventative treatments for COVID-19. However, throughout the pandemic, a UK-wide approach to the procurement of therapeutics has been taken and has proven vital to allow the UK to have the buying power to secure significant numbers of therapeutics in a competitive global market. A UK-wide approach has also been taken on the development and implementation of clinical prescribing policies for COVID-19 therapeutics. This has ensured patients across the UK have had equal access to safe and effective medicines for COVID-19.

I refer the member to the answer to question S6W-09978 on 24 August 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.

The Scottish Stroke Improvement Programme report, published on 28 June, includes data from the Scottish Stroke Care Audit (SSCA). The SSCA measures quality of care of stroke services in each acute hospital, grouped by NHS board against the Scottish Stroke Care Standards.

I refer the member to the answer to question S6W-10433 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.

All beavers that have been captured in Tayside and translocated to projects in Scotland, England and Wales are subject to disease screening and appropriate treatment as a licence condition prior to release. This screening ensures that beavers released under licence from NatureScot are not carrying Giardia prior to any translocations.

Our vision is for everyone with rehabilitation needs to be able to access the care and support they need to live well, on their own terms.

Defined performance markers such as access to acute therapy, access to inpatient stroke therapy, access to community stroke therapy and six-month reviews are being included in the refreshed Stroke Improvement Plan, and annual board reviews carried out by the Scottish Stroke Improvement Programme Team, led by the Scottish Stroke Improvement Programme Lead, will assess rehabilitation performance against these targets.